IP Library › Granted Patent US 12,600,797
Granted Patent B2
US 12,600,797 · App. 17/915,885 · Granted Apr 14, 2026

Fibrin-binding antibody and pharmaceutical composition containing antibody

Inventors: Yasuhiro Matsumura (Chiba, JP); Shingo Hanaoka (Chiba, JP); Shinji Saijo (Chiba, JP)
Assignees: RIN INSTITUTE INC.; NATIONAL CANCER CENTER
C07K16/36A61P35/00C07K2317/24C07K2317/565
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,600,797
App. No.
17/915,885
Granted
Apr 14, 2026
Kind
B2
Abstract

The present invention provides an antibody that binds to fibrin and a pharmaceutical composition containing the antibody. According to the present invention, there is particularly provided a humanized antibody that binds to fibrin and a pharmaceutical composition containing the antibody.

Claims (13)

1 . An antibody that binds to insoluble fibrin or an antigen-binding fragment thereof, comprising

(1) a heavy chain variable region comprising heavy chain CDR1 having an amino acid sequence set forth in SEQ ID NO:1, heavy chain CDR2 having an amino acid sequence set forth in SEQ ID NO:2 and heavy chain CDR3 having an amino acid sequence set forth in SEQ ID NO:3, and

a light chain variable region comprising light chain CDR 1 having an amino acid sequence set forth in SEQ ID NO:4, light chain CDR2 having an amino acid sequence set forth in SEQ ID NO:5 and Light chain CDR3 having an amino acid sequence set forth in SEQ ID NO:6; or

(2) a heavy chain variable region comprising heavy chain CDR1 having an amino acid sequence set forth in SEQ ID NO:9, heavy chain CDR2 having an amino acid sequence set forth in SEQ ID NO:10 and heavy chain CDR3 having an amino acid sequence set forth in SEQ ID NO:11, and

a light chain variable region comprising light chain CDR1 having an amino acid sequence set forth in SEQ ID NO:12, light chain CDR2 having an amino acid sequence set forth in SEQ ID NO:13 and light chain CDR3 having an amino acid sequence set forth in SEQ ID NO:14.

2 . The antibody that binds to insoluble fibrin or an antigen-binding fragment thereof according to claim 1 , comprising

(3) a heavy chain variable region having an amino acid sequence set forth in SEQ ID NO:7 and a light chain variable region having an amino acid sequence set forth in SEQ ID NO:8; or

(4) a heavy chain variable region having an amino acid sequence set forth in SEQ ID NO:15 and a light chain variable region having an amino acid sequence set forth in SEQ ID NO:16.

3 . The antibody or an antigen-binding fragment thereof according to claim 1 , which is a humanized antibody or an antigen-binding fragment thereof.

4 . An antibody-drug conjugate comprising the antibody or an antigen-binding fragment thereof according to claim 1 .

5 . A pharmaceutical composition comprising the antibody-drug conjugate according to claim 4 .

6 . A method of treating cancer in a subject, the method comprising administering the pharmaceutical composition according to claim 5 to the subject.

7 . An in-vivo diagnostic agent comprising the antibody or an antigen-binding fragment thereof according to claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2026
From: RIN INSTITUTE INC.
To: CAST BIO INC.
Reel/Frame 075045/0042 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2022
From: MATSUMURA, YASUHIRO; HANAOKA, SHINGO; SAIJO, SHINJI
To: NATIONAL CANCER CENTER; RIN INSTITUTE INC.
Reel/Frame 061299/0029 →
Priority Claims (1)
JP 2020-061975 · Mar 31, 2020 · national
Continuity (1)
Related Publication 20230132177A1 · Apr 27, 2023
References Cited (22)
US 8877195B2 · Akassoglou · 2014 [cited by applicant]
US 9429584B2 · Matsumura · 2016 [cited by examiner]
US 11311626B2 · Matsumura · 2022 [cited by examiner]
US 20120183560A1 · Akassoglou · 2012 [cited by applicant]
US 20160011217A1 · Matsumura et al. · 2016 [cited by applicant]
US 20200147231A1 · Matsumura et al. · 2020 [cited by applicant]
EP 3620471A1 · 2020 [cited by applicant]
TW 201842938A · 2018 [cited by applicant]
WO WO2011158973A1 · 2011 [cited by applicant]
WO WO2014133093A1 · 2014 [cited by examiner]
WO WO2016167227A1 · 2016 [cited by applicant]
WO WO2018203517A1 · 2018 [cited by examiner]
Dvorak et al., “Chapter 57: Malignancy and Hemostasis.” [cited by applicant]
Dvorak, “Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy,” J. Clin. Oncol. 20:4368-80 (Nov. 2002). [cited by applicant]
Matsumura, “Cancer and Blood Coagulation.” [cited by applicant]
Office Action dated Aug. 17, 2024, for Chinese Patent Application No. 202180025986.6, Matsumura et al., “Fibrin-binding Antibody and Pharmaceutical Composition Containing Same,” filed Mar. 30, 2021 (4 pages). [cited by applicant]
Office Action dated Feb. 23, 2024, for Chinese Patent Application No. 202180025986.6, Matsumura et al., “Fibrin-binding antibody and pharmaceutical composition containing same,” filed Mar. 30, 2021 (8 pages). [cited by applicant]
Office Action dated Sep. 5, 2024, for Taiwanese Patent Application No. 110111843, Matsumura et al., “Fibrin-binding antibody and pharmaceutical composition containing antibody,” filed Mar. 31, 2021 (6 pages). [cited by applicant]
International Search Report mailed Apr. 27, 2021 for International Application No. PCT/JP2021/013512, Matsumura et al., “Fibrin-Binding Antibody and Pharmaceutical Composition Containing Antibody,” filed Mar. 30, 2021 (… [cited by applicant]
Matsumura, “Cancer Stromal Targeting Therapy,” Yakugaku Zasshi 137(5):529-534 (2017) (English translation) (13 pages). [cited by applicant]
Extended European Search Report dated Feb. 2, 2024, for European Patent Application No. 21780242.0, Matsumura et al., “Fibrin-Binding Antibody and Pharmaceutical Composition Containing Antibody,” filed Mar. 30, 2021 (9 … [cited by applicant]
Fuchigami et al., “Chemotherapy payload of anti-insoluble fibrin antibody-drug conjugate is released specifically upon binding to fibrin,” Sci Rep. 8(1):14211 (Sep. 2018) (9 pages). [cited by applicant]